Rosiglitazone, brand name Avandia, is a thiazolidinedione (TZD) that lowers A1C by 1 to 1.5 percent by improving the body’s response to insulin. Its history is dominated by the 2007 cardiovascular controversy and subsequent REMS restrictions that were eventually lifted after the RECORD trial showed non-inferiority. The drug remains FDA-approved but is rarely prescribed today, with pioglitazone preferred within the TZD class for most indications.
How Rosiglitazone Works
Rosiglitazone activates PPAR-gamma (peroxisome proliferator-activated receptor gamma), a nuclear receptor in fat, muscle, and liver. Activation drives gene transcription changes that improve insulin sensitivity in peripheral tissues, reduce hepatic glucose output, and shift fat distribution. The mechanism is genomic, so effects build over weeks rather than minutes.
- Drug class: thiazolidinedione (glitazone)
- Brand name: Avandia
- Generic status: yes
- Half-life: 3 to 4 hours
- Metabolism: hepatic (CYP2C8 primary, CYP2C9 secondary)
- Onset of glucose effect: weeks
- Full A1C effect: 8 to 12 weeks
Approved Uses
- Adjunct to diet and exercise in adults with type 2 diabetes
- Monotherapy or in combination with metformin, sulfonylureas, or insulin
- Not used for type 1 diabetes or diabetic ketoacidosis
Typical Dosing
| Population | Starting Dose | Maintenance | Maximum |
|---|---|---|---|
| Adults without HF | 4 mg once daily or 2 mg twice daily | 4 to 8 mg | 8 mg/day |
| NYHA Class I or II HF | Use with caution; lower dose | Close monitoring | Reduced |
| NYHA Class III or IV | Contraindicated | Contraindicated | Contraindicated |
| With insulin | 4 mg/day | Watch edema, hypoglycemia | 4 mg/day in many cases |
The 8 mg dose is typically reached 8 to 12 weeks after starting at 4 mg, based on fasting glucose response and absence of edema or weight gain.
Effect on A1C and Other Outcomes
- A1C reduction: 1.0 to 1.5 percent
- Fasting glucose: 30 to 50 mg/dL reduction
- HDL cholesterol: rises modestly
- LDL cholesterol: rises 10 to 20 percent — slightly worse than pioglitazone
- Triglycerides: smaller reductions than pioglitazone
- Adipose redistribution: subcutaneous over visceral
The Cardiovascular Controversy
The story of rosiglitazone’s near-removal and rehabilitation is one of the most-studied episodes in diabetes drug history.
| Year | Event |
|---|---|
| 1999 | Rosiglitazone approved by FDA |
| 2006 | ADOPT trial published — rosiglitazone monotherapy had the lowest rate of secondary failure at 5 years compared with metformin and glyburide |
| May 2007 | Nissen and Wolski meta-analysis (NEJM) of 42 short-term trials suggests 43% relative increase in MI risk |
| 2008-2009 | FDA convenes advisory committees; intense scrutiny |
| June 2009 | RECORD trial published in Lancet — designed to test CV outcomes; showed non-inferiority for primary endpoint (CV hospitalization or death) |
| September 2010 | FDA imposes REMS restricting access |
| November 2013 | FDA removes REMS restrictions after re-adjudication of RECORD data confirms CV non-inferiority |
| 2015+ | Use remains low; pioglitazone preferred for most TZD indications |
What RECORD Showed
The RECORD trial (Home et al., Lancet 2009) randomized 4,447 patients with type 2 diabetes inadequately controlled on metformin or sulfonylurea to add rosiglitazone or to switch combinations. Over a mean 5.5 years of follow-up:
- Primary endpoint (CV hospitalization or death): non-inferior
- Myocardial infarction: numerically increased but not statistically significant
- Stroke: no difference
- Heart failure: increased (consistent with known TZD effect)
- Bone fractures: increased in women, consistent with class
The trial design and follow-up have been criticized but a 2013 re-adjudication by an independent academic team confirmed the original conclusions, which led directly to the FDA removing the REMS.
Side Effects
Common
- Weight gain — 3 to 5 kg over the first year
- Edema — 5 to 15 percent
- Upper respiratory tract infection
- Sinusitis
- Headache, back pain
- Mild anemia (hemoglobin drop 0.5 to 1 g/dL)
Serious
- Heart failure precipitation (boxed warning)
- Fracture risk roughly 2x in postmenopausal women
- Macular edema (rare)
- Hepatic enzyme elevations (uncommon)
- Hypoglycemia (rare alone; common with insulin or sulfonylureas)
- Allergic skin reactions (rare)
What Rosiglitazone Does Not Cause
- Bladder cancer signal — unlike pioglitazone, rosiglitazone has not shown a bladder cancer association
Rosiglitazone Compared with Pioglitazone
| Feature | Rosiglitazone | Pioglitazone |
|---|---|---|
| Generic available | Yes | Yes |
| A1C drop | 1.0 to 1.5% | 1.0 to 1.5% |
| Weight gain | 3 to 5 kg | 3 to 5 kg |
| Edema | 5 to 15% | 5 to 15% |
| HF precipitation | Yes (boxed) | Yes (boxed) |
| Fracture risk | Yes (postmenopausal women) | Yes (postmenopausal women) |
| LDL cholesterol | Rises 10 to 20% | Smaller rise |
| Triglycerides | Smaller reduction | 10 to 20% reduction |
| Bladder cancer | No signal | Small contested signal |
| CV outcomes | Non-inferior (RECORD) | Possible MACE benefit (PROactive secondary) |
| Cost/month | $30 to $70 generic | $10 to $30 generic |
| Current preference | Rarely used | Preferred TZD |
Who Should Not Take Rosiglitazone
- NYHA Class III or IV heart failure
- Severe liver disease
- Type 1 diabetes or diabetic ketoacidosis
- Pregnancy and breastfeeding
- Macular edema
- Known hypersensitivity
- Recent acute coronary syndrome (relative caution)
Use With Caution
- NYHA Class I or II heart failure
- Established cardiovascular disease — newer drug classes are preferred
- Postmenopausal women with osteoporosis risk
- Combination with insulin (higher edema and weight gain)
- Elderly patients
Drug Interactions
- Gemfibrozil — strong CYP2C8 inhibitor; doubles rosiglitazone exposure
- Rifampin — strong CYP2C8 inducer; lowers rosiglitazone levels by 65 percent
- Insulin — additive edema, weight gain, hypoglycemia
- Sulfonylureas — additive hypoglycemia and weight gain
- NSAIDs — worsen sodium retention
- Trimethoprim — moderate CYP2C8 inhibitor
Where Rosiglitazone Fits in 2024 Care
The ADA Standards of Care 2024 mention TZDs as one option for add-on therapy to metformin when cost matters and other considerations align. In practice, pioglitazone is preferred over rosiglitazone within the class because of the slightly better lipid profile and the lingering associations from the 2007 to 2013 controversy. Patients already stable on rosiglitazone with good control and tolerance can usually continue; clinicians starting a TZD today almost always pick pioglitazone.
Monitoring
- Weight — weekly self-checks for first 3 months
- Edema — daily self-check
- Blood pressure — each visit
- A1C — every 3 months until stable
- Liver function — baseline; rechecking if symptoms
- Lipid panel — annually (LDL increases expected)
- Eye exam — annually; vision changes investigated promptly
- Bone density — consider in postmenopausal women
Practical Tips
- Take the same time each day, with or without food
- Weigh weekly during titration
- Check ankles daily for swelling
- Maintain a lower-sodium diet (around 2 g/day)
- Engage in weight-bearing exercise
- Discuss bone density with your clinician if postmenopausal
- Tell every clinician about all your diabetes medications
- If insurance prefers rosiglitazone over pioglitazone, ask whether the switch is reasonable for you
Related Reading
See our companion guides on pioglitazone (Actos) and pioglitazone side effects for the preferred TZD within the class. The treatment overview places Avandia in the broader landscape, and the complications and related conditions guide adds context on the cardiovascular and renal considerations that drive modern drug choice.
The Bottom Line
Avandia (rosiglitazone) is a TZD that lowers A1C by 1 to 1.5 percent through PPAR-gamma activation. After a turbulent regulatory history — the 2007 Nissen meta-analysis, REMS restrictions, and the eventual RECORD trial vindication — it remains FDA-approved but rarely used. Within the class, pioglitazone is generally preferred because of a slightly better lipid profile, possible MACE benefit, and the reputational hangover that still attaches to rosiglitazone. Both drugs share the same boxed warning for heart failure, the same edema and weight gain trade-offs, and the same fracture risk in postmenopausal women. Rosiglitazone has no bladder cancer signal, which is one of its few comparative advantages. Talk to your clinician about whether a TZD makes sense at all, and if so, which one fits your specific situation.
